#DiabetesManagement #HeartHealth #HealthyLifestyle
hsph.harvard.edu
GLP-1 drugs combined with healthy lifestyle habits linked with reduced cardiovascular risk among diabetes patients | Harvard T.H. Chan School of Public Health
Boston, MA -- Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.
#GLP1 #WeightLoss #DiabetesManagement
www.businessinsider.com
Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch.
The pill, which analysts say might cost $300 a month, could be available as soon as mid-2026.
Better injections and better pills.
